AstraZeneca wins approval for Imfinzi in NSCLC perioperative setting
The FDA approval of Imfinzi in this indication comes a month after the agency called for an overhaul of perioperative lung cancer trials.
The FDA approval of Imfinzi in this indication comes a month after the agency called for an overhaul of perioperative lung cancer trials.
What's Your Reaction?
